Search Results for “Roche” – Page 23 – media

Johnson & Johnson under Justice Department Scrutiny for Funding Iraqi Terrorism

After the disclosure from AstraZeneca that it’s under Justice Department scrutiny for illegally funding Iraqi terrorism, Roche and Johnson & Johnson revealed similar inquiries from the agency.
- Source: FiercePharma
- 557
- August 6, 2018
Company Insight lawsuit pharmaceutical company
Filing Lawsuit Against Drugmakers for Funding Terrorism

Last year, around 100 veterans filed a bombshell lawsuit against several drugmakers, by accusing that they funded terrorism by paying high bribes to win contracts with the Iraqi Ministry of Health. At present, the Department of Justice is investigating similar accusations, as per AstraZeneca securities filing which says that it's part of the probe.
- Source: FiercePharma
- 1,046
- August 3, 2018
AstraZeneca Company Insight pharmaceutical
Invention of Cortisol Detecting Wearable to Measure Stress

The research team from Stanford University have invented a novel wearable that could measure the level of a patient’s cortisol from their sweat. Cortisol is a hormone linked to stress, which takes several days to test. This scientific discovery was recently published in Science Advances.
- Source: MobiHealthNews
- 680
- July 25, 2018
digital health Researches wearables
Study Unravels New Protein Complex that Repairs Broken DNA Ends

In a major breakthrough in cancer research, a team of scientists from the University of Toronto, The Institute of Cancer Research, London, The Netherlands Cancer Institute and the University of Bern have discovered how cells repair damaged strands of DNA. They revealed a brand new protein complex in cells that protect broken DNA ends and causes its repair, in their study published in Nature on Wednesday.
- Source: News Medical
- 826
- July 23, 2018
cancer DNA Researches
Development of Eye Drop for AMD

Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly. The most commonly used drugs to slow the progression of the disease is Roche’s Lucentis and Regeneron’s Eylea. These drugs are injected into the eye which, needless to say, leads to more inconvenience.
- Source: FierceBiotech
- 882
- July 23, 2018
blindness Clinical Trials
Recent Study Reports on Liver Cancer Risks and Detection

HCC or hepatocellular carcinoma can result in patients getting liver diseases such as viral hepatitis and non-alcoholic fatty liver disease with cirrhosis due to disease progression. New data from recent researches shows factors that improve early detection and diagnosis, and risks prior to HCC and during treatment.
- Source: Healio
- 565
- July 19, 2018
liver cancer Researches
Novartis Shuts Down Its Antimicrobial Research

Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
- Source: Fierce Biotech
- 731
- July 16, 2018
AMR antibiotic resistance Company Insight
Genentech Lawsuit against Eli Lilly’s Antipsoriasis Drug TALZ

Genentech recently won the patent for a psoriasis drug. Unfortunately, Roche’s Genentech unit prosecuted Eli Lilly for violation by claiming their psoriasis drugTalz, infringes on one of their patents.
- Source: FiercePharma
- 970
- July 9, 2018
Company Insight Eli Lilly lawsuit psoriasis Roche
PharmaAsia Recap

Recent news regarding pharma companies in Asia
- Source: FiercePharma
- 733
- July 3, 2018
Asia Market Views pharmaceutical company
Array BioPharma gets FDA Approval for Melanoma Combo

The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
- Source: FiercePharma
- 595
- June 28, 2018
cancer Melanoma New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.